Safety and efficacy data published for novel nusinersen drug delivery method for spinal muscular atrophy patients

STRASBURG, PA – A recently published paper details the safety and efficacy of nusinersen administration via a subcutaneous intrathecal catheter system (SIC) for SMA patients with advanced disease. SMA is a devastating genetic disease that leads to progressive degeneration of motor neurons that control movement, swallowing, and breathing. The novel SIC system is comprised of an intrathecal catheter that’s connected to an implantable infusion port. The SIC system was created to address the complications of nusinersen delivery derived from significant spinal deformities or fusions commonly found in SMA patients.

Enjoy our Fall 2021 Newsletter!

The journey to a rare genetic diagnosis can be a long odyssey for many families. In our latest edition of the Clinic for Special Children newsletter, read a story of a family living with an ultra rare disorder, learn about our genetic testing pipeline at the Clinic, and see how we’ve worked with collaborators to develop our Plain Insight Panel™ test.

CLICK HERE to read the latest issue now!


Dr. Kevin A. Strauss author on largest published safety study for Spinal Muscular Atrophy (SMA) gene therapy

Dr. Kevin A. Strauss, Medical Director at the Clinic for Special Children, was an author on a recently published research paper, Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy. This paper explores safety for onasemonogene abeparvovec therapy (gene therapy for Spinal Muscular Atrophy).

The study is the largest international safety study published thus far. Dr. Strauss contributed to the paper as the Clinic for Special Children served as a clinical site for the phase 3 SPR1NT study of the gene therapy. SMA is the most common genetic cause of infant death worldwide and causes progressive degeneration of motor nerve cells in the spinal cord and brainstem.

To read the full paper, please visit the link HERE.